Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

181.80 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
80 81 Next >
The Smartest Dividend Stocks to Buy With $500 Right Now
Some prominent healthcare and consumer stocks have fallen out of favor with the market, so now is the time to pounce on some great deals. 
Via The Motley Fool
25 Top Dividend Stocks to Buy and Hold in 2025
Via The Motley Fool
2 No-Brainer Dividend Stocks to Buy With $250 in 2025
Via The Motley Fool
Time to Dump or Double Up on SCHD?
SCHD shares have fallen nearly 10% in a month. 
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
Via The Motley Fool
Looking Into AbbVie's Recent Short Interest
Via Benzinga
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Is AbbVie Stock a Buy?
Via The Motley Fool
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Healthcare And Biotech Stocks Continue Their Slide
Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December. 
Via Talk Markets
Topics ETFs Stocks / Equities
Stocks Going Ex Dividend In January 2025
The following is a short list of some of the many stocks going ex-dividend during the next month. 
Via Talk Markets
Topics Stocks / Equities
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:GSK),(NASDAQ:AZN),(NYSE:ABBV),(NASDAQ:CRDF) EQNX::TICKER_END 
Via FinancialNewsMedia
2 Excellent Dividend Stocks to Buy on the Dip
Via The Motley Fool
Analyst Scoreboard: 19 Ratings For AbbVie
Via Benzinga
Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook
From FN Media Group LLC
Via GlobeNewswire
The Smartest Dividend Stocks to Buy With $1,000 Right Now
Via The Motley Fool
Check Out What Whales Are Doing With ABBV
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
Introducing the "Dividend Seven" Stocks
Via The Motley Fool
Schwab US Dividend Equity ETF Reverses In December: What's Going On?
The Schwab US Dividend Equity ETF has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be plaguing the fund: 
Via Benzinga
Topics ETFs
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off
Via The Motley Fool
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Via The Motley Fool
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
Via The Motley Fool
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back?
AbbVie has a lofty goal in cancer treatment, and it could come to fruition in 2025. 
Via Investor's Business Daily
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies have ingrained competitive advantages in an evergreen industry backed by decades of dividend growth. 
Via The Motley Fool
Neurocrine Wins FDA Approval For Genetic Disorder Drug
The company can launch within a week, says Chief Executive Kyle Gano. 
Via Investor's Business Daily
Exposures Product Safety
1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever
Via The Motley Fool
Topics Stocks
Exposures US Equities
AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study
AbbVie reports Phase 3 TEMPO-2 trial success for tavapadon, a once-daily Parkinson's treatment, showing significant symptom improvement and safety. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
80 81 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.